Dataset: 11.1K articles from the COVID-19 Open Research Dataset (PMC Open Access subset)
All articles are made available under a Creative Commons or similar license. Specific licensing information for individual articles can be found in the PMC source and CORD-19 metadata
.
More datasets: Wikipedia | CORD-19

Logo Beuth University of Applied Sciences Berlin

Made by DATEXIS (Data Science and Text-based Information Systems) at Beuth University of Applied Sciences Berlin

Deep Learning Technology: Sebastian Arnold, Betty van Aken, Paul Grundmann, Felix A. Gers and Alexander Löser. Learning Contextualized Document Representations for Healthcare Answer Retrieval. The Web Conference 2020 (WWW'20)

Funded by The Federal Ministry for Economic Affairs and Energy; Grant: 01MD19013D, Smart-MD Project, Digital Technologies

Imprint / Contact

Results for Query ‹ SARS-associated coronavirus pneumonia medication

2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies – Alternative medication

Middle East respiratory syndrome (MERS) – Infection Control Aspects

Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China – 6.2. General Treatment

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses – Potential therapeutic strategies against COVID-19

Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China – 6.3. Treatment of Severe and Critical Cases

A precision medicine approach to managing 2019 novel coronavirus pneumonia – Precision treatment for 2019-nCoV pneumonia

COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses – Vaccines for SARS-CoV-2

Glucocorticosteroid in Treatment of Severe Pneumonia – 8. Conclusion

COVID-19: Knowns, Unknowns, and Questions – (vi) Can we find therapeutic options? :::

Glucocorticosteroid in Treatment of Severe Pneumonia – 7.2. SARS

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status – Current therapies

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status – Antiviral treatments

COVID-19: Knowns, Unknowns, and Questions – (viii) What is the host response to SARS-CoV-2 and pathology of COVID-19? :::

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): A Perpetual Challenge – Management

Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective – Conventional treatment of SARS-CoV-2: is there a room for Chinese medicine?

2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies – Protection

Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19 – Clinical course and outcomes

A precision medicine approach to managing 2019 novel coronavirus pneumonia – Precision prevention and control for 2019-nCoV pneumonia

Middle East respiratory syndrome (MERS) – Prognosis

SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat – Chemotherapeutic options for SARS-CoV-2 infection

Antiviral Treatment Guidelines for Middle East Respiratory Syndrome – 4. Framing key questions

Antiviral Treatment Guidelines for Middle East Respiratory Syndrome – 5. Searching for evidence

Identification of New Respiratory Viruses in the New Millennium – 3.2. Coinfections with hMPV

Coronaviruses and the human airway: a universal system for virus-host interaction studies – Therapy

SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat – Conclusion remarks